GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Greater Cannabis Company GCAN · USD

N/A · US listing · 🇺🇸 United States

Compare

About Greater Cannabis Company

Its shares trade under the ticker GCAN. It has been listed since 9 July 2018.

The Greater Cannabis Co., Inc. engages in the business of cannabis related investment and development opportunities through online retail store, direct equity investments, joint ventures, licensing agreements, or acquisitions. The company is headquartered in Baltimore, Maryland. The company went IPO on 2018-07-09. The firm conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The firm conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
9 Jul 2018
Employees
1
Website
gcanrx.com ↗

Leadership

Pay as last reported

  • Mr. Aitan ZacharinPresident, Chief Executive Officer, Treasurer, Director, since 2018$120,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Baltimore, Maryland with a single full-time employee.
  • Conducts medical research and clinical trials for cannabis-based treatments focusing on neuropsychiatric disorders.
  • Uses bio-adhesive, adjustable dose, and fully dissolvable patch technology for drug delivery.

Weaknesses

  • Operates with only one full-time employee, indicating limited workforce capacity.
  • Sector and industry classifications are listed as N/A, suggesting unclear market positioning.
  • IPO occurred in 2018, which may indicate a relatively new or unproven market presence.

Opportunities

  • Pursuing clinical trials for cannabis-based treatments could lead to new medical applications.
  • Expanding cannabis-related investment and development opportunities through various business models.
  • Commercializing cannabinoid-based therapeutics may open new revenue streams.

Threats

  • Unspecified sector and industry may hinder strategic planning and market analysis.
  • Limited workforce could impede growth and operational scalability.
  • IPO in 2018 may face challenges in sustaining investor interest over time.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.